Survival curves for men treated with and without add-on docetaxel converged with longer follow-up. Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized ...

Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hematopoietic Growth Factor PIXY321 After Moderate-Dose Fluorouracil, Doxorubicin, and Cyclophosphamide in Stage II and III Breast ...

(HealthDay News) — Chemotherapy at the start of androgen-deprivation therapy (ADT) can extend the lives of men with metastatic, hormone-sensitive prostate cancer, according to research published ...

Factors affecting long-term outcomes after postchemotherapy surgery in patients with nonseminomatous germ cell tumors of the mediastinum. Epidermal growth factor receptor (EGFR) targeted therapy in ...

Docetaxel rechallenge was tied to improved overall survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) who did not experience disease progression on ...

Research by a Washington State University-led team of scientists has identified a receptor protein, CHRM1, as a key player in prostate cancer (PC) cells’ resistance to docetaxel (DTX), a chemotherapy ...

Magrolimab plus docetaxel improved outcomes in metastatic NSCLC patients with high CD47 expression, showing a median PFS of 8.9 months versus 2.6 months for lower expression. The ELEVATELung&UC trial ...

(RTTNews) - Sagent Pharmaceuticals has recalled two lots of chemotherapy drug Docetaxel Injection, USP due to potential presence of particulate matter from the stopper in the drug, according to the ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated ...